Nature Communications (Jan 2022)
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
- Yosuke Tanaka,
- Reina Takeda,
- Tsuyoshi Fukushima,
- Keiko Mikami,
- Shun Tsuchiya,
- Moe Tamura,
- Keito Adachi,
- Terumasa Umemoto,
- Shuhei Asada,
- Naoki Watanabe,
- Soji Morishita,
- Misa Imai,
- Masayoshi Nagata,
- Marito Araki,
- Hitoshi Takizawa,
- Tomofusa Fukuyama,
- Chrystelle Lamagna,
- Esteban S. Masuda,
- Ryoji Ito,
- Susumu Goyama,
- Norio Komatsu,
- Tomoiku Takaku,
- Toshio Kitamura
Affiliations
- Yosuke Tanaka
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- Reina Takeda
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- Tsuyoshi Fukushima
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- Keiko Mikami
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- Shun Tsuchiya
- Department of Hematology, Juntendo University Graduate School of Medicine
- Moe Tamura
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- Keito Adachi
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- Terumasa Umemoto
- International Research Center for Medical Sciences, Kumamoto University
- Shuhei Asada
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- Naoki Watanabe
- Department of Hematology, Juntendo University Graduate School of Medicine
- Soji Morishita
- Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine
- Misa Imai
- Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine
- Masayoshi Nagata
- Department of Urology, Juntendo University Graduate School of Medicine
- Marito Araki
- Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine
- Hitoshi Takizawa
- International Research Center for Medical Sciences, Kumamoto University
- Tomofusa Fukuyama
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- Chrystelle Lamagna
- Rigel, South San Francisco
- Esteban S. Masuda
- Rigel, South San Francisco
- Ryoji Ito
- Central Institute for Experimental Animals
- Susumu Goyama
- Division of Molecular Oncology Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
- Norio Komatsu
- Department of Hematology, Juntendo University Graduate School of Medicine
- Tomoiku Takaku
- Department of Hematology, Juntendo University Graduate School of Medicine
- Toshio Kitamura
- Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo
- DOI
- https://doi.org/10.1038/s41467-021-27928-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 13
Abstract
Leukemic stem cells (LSCs) in chronic myeloid leukemia are resistant to imatinib and therefore are a cause of relapse. The authors show that IRAK1/4-NF-κB-PD-L1 signaling is critical to mediate imatinib resistance in LSCs and that combining imatinib with blocking this signalling pathway can eliminate LSCs.
